Yusuke Watanabe1, Sho Endo2, Kazuyoshi Nishihara2, Keijiro Ueda3, Mari Mine4, Sadafumi Tamiya4, Toru Nakano2, Masao Tanaka5. 1. Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokrakita-ku, Kitakyushu, 802-0077, Japan. wyuusuke@surg1.med.kyushu-u.ac.jp. 2. Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokrakita-ku, Kitakyushu, 802-0077, Japan. 3. Department of Gastroenterology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokrakita-ku, Kitakyushu, 802-0077, Japan. 4. Department of Pathology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokrakita-ku, Kitakyushu, 802-0077, Japan. 5. Department of Surgery, Shimonoseki City Hospital, 1-13-1 Koyo-cho, Shimonoseki, 750-8520, Japan.
Abstract
PURPOSE: This study was performed to evaluate the surgical indication for intraductal papillary mucinous neoplasm (IPMN) advocated by the 2017 revised International Association of Pancreatology consensus guidelines (IAPCG2017). METHODS: The medical records of 63 patients who underwent pancreatectomy for IPMN were retrospectively reviewed. RESULTS: Thirteen patients had main-duct IPMN, 25 had mixed IPMN, and 25 had branch-duct IPMN with frequencies of high-grade dysplasia or invasive carcinoma of 62, 24, and 28%, respectively. The sensitivity and specificity of high-risk stigmata for high-grade dysplasia or invasive carcinoma advocated by the IAPCG2017 were 90 and 67%, respectively. Of 17 patients with invasive carcinoma, all patients had high-risk stigmata, and 16 had an enhanced mural nodule (MN) of ≥ 5 mm. The sensitivity and specificity of a ≥ 5-mm enhanced MN for predicting invasive carcinoma were 94% and 87%, respectively. CONCLUSIONS: Introducing a size threshold for enhanced MNs into the assessment of high-risk stigmata increases the specificity without jeopardizing the sensitivity. The surgical indication for any type of IPMN may be determined using only a ≥ 5-mm enhanced MN. When the type of IPMN is classified strictly, about half of IPMNs are mixed type, and most are benign. The surgical indication for mixed IPMN should be reconsidered.
PURPOSE: This study was performed to evaluate the surgical indication for intraductal papillary mucinous neoplasm (IPMN) advocated by the 2017 revised International Association of Pancreatology consensus guidelines (IAPCG2017). METHODS: The medical records of 63 patients who underwent pancreatectomy for IPMN were retrospectively reviewed. RESULTS: Thirteen patients had main-duct IPMN, 25 had mixed IPMN, and 25 had branch-duct IPMN with frequencies of high-grade dysplasia or invasive carcinoma of 62, 24, and 28%, respectively. The sensitivity and specificity of high-risk stigmata for high-grade dysplasia or invasive carcinoma advocated by the IAPCG2017 were 90 and 67%, respectively. Of 17 patients with invasive carcinoma, all patients had high-risk stigmata, and 16 had an enhanced mural nodule (MN) of ≥ 5 mm. The sensitivity and specificity of a ≥ 5-mm enhanced MN for predicting invasive carcinoma were 94% and 87%, respectively. CONCLUSIONS: Introducing a size threshold for enhanced MNs into the assessment of high-risk stigmata increases the specificity without jeopardizing the sensitivity. The surgical indication for any type of IPMN may be determined using only a ≥ 5-mm enhanced MN. When the type of IPMN is classified strictly, about half of IPMNs are mixed type, and most are benign. The surgical indication for mixed IPMN should be reconsidered.
Authors: Olca Basturk; Seung-Mo Hong; Laura D Wood; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Lodewijk A A Brosens; Noriyoshi Fukushima; Michael Goggins; Ralph H Hruban; Yo Kato; David S Klimstra; Günter Klöppel; Alyssa Krasinskas; Daniel S Longnecker; Hanno Matthaei; G Johan A Offerhaus; Michio Shimizu; Kyoichi Takaori; Benoit Terris; Shinichi Yachida; Irene Esposito; Toru Furukawa Journal: Am J Surg Pathol Date: 2015-12 Impact factor: 6.394
Authors: Georgios Gemenetzis; Fabio Bagante; James F Griffin; Neda Rezaee; Ammar A Javed; Lindsey L Manos; Anne M Lennon; Laura D Wood; Ralph H Hruban; Lei Zheng; Atif Zaheer; Elliot K Fishman; Nita Ahuja; John L Cameron; Matthew J Weiss; Jin He; Christopher L Wolfgang Journal: Ann Surg Date: 2017-08 Impact factor: 12.969
Authors: Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa Journal: Virchows Arch Date: 2005-08-09 Impact factor: 4.064
Authors: Selma J Lekkerkerker; Marc G Besselink; Olivier R Busch; Joanne Verheij; Marc R Engelbrecht; Erik A Rauws; Paul Fockens; Jeanin E van Hooft Journal: Gastrointest Endosc Date: 2016-09-29 Impact factor: 9.427